q3 2018 conference call - s24.q4cdn.com · 10/25/2018 · q3 2018 conference call mark alles,...

Q3 2018 Conference CallOctober 25, 2018

CHANGING THE COURSE OFHUMAN HEALTH THROUGH BOLD

PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Q3 2018 Conference Call

Mark Alles, Chairman & Chief Executive Officer

Nadim Ahmed, President, Hematology & Oncology

Jay Backstrom, MD, Chief Medical Officer

Q&A

Terrie Curran, President, I&I

David Elkins, Chief Financial Officer

2

Forward-Looking Statements and Adjusted Financial Information

3

This presentation contains forward-looking statements, which are generally statements that are not historical facts.Forward-looking statements can be identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,”“plans,” “will,” “outlook,” “targets” and similar expressions. Forward-looking statements are based on management’scurrent plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertakeno obligation to update any forward-looking statement in light of new information or future events, except as otherwiserequired by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult topredict and are generally beyond our control. Actual results or outcomes may differ materially from those implied bythe forward-looking statements as a result of the impact of a number of factors, many of which are discussed in moredetail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.

In addition to unaudited financial information prepared in accordance with U.S. GAAP, this presentation also containsadjusted financial measures. Further information relevant to the interpretation of adjusted financial measures, andreconciliations of these adjusted financial measures to the most comparable GAAP measures, may be found in theAppendix and on our website at www.Celgene.com in the “Investor Relations” section.

Mark AllesChairman & Chief Executive Officer


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Q3 2018: Strong Performance and Pipeline Momentum

Delivering Excellent Operating Results− Outstanding year-over-year top- and bottom-line growth − Raising 2018 financial guidance and reaffirming 2020 outlook

Accelerating Inline, Late-Stage Products and Early Pipeline− More than 10 positive Ph III trials across portfolio year-to-date− Advancing 5 late-stage assets expected to launch by 2020 – ozanimod, fedratinib,

luspatercept, liso-cel and bb2121− R&D engine progressing; 5 INDs filed for high-potential new medicines year-to-date

Strengthening the Organization− Establishing dedicated global clinical drug development function− Alise Reicin, MD, appointed as President, Global Clinical Development− Aligns with mission to discover, develop and commercialize innovative medicines

5

David ElkinsChief Financial Officer


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Q3 2018 Financial Highlights

7

Strong Operating Results Driven by Volume− Net product sales grew 18% Y/Y; Adjusted diluted EPS $2.29 (+20% Y/Y)− 15 of the 18 percentage points of net product sales growth from volume

Strategic and Balanced Capital Deployment to Support Future Growth− On track to invest ~$3.6B in R&D in FY2018− Reaffirm 2020 outlook: $19B-$20B total revenue and >$12.50 adjusted EPS

2018 Total Revenue, OTEZLA® Net Sales and Adj. Diluted EPS Guidance Raised− Total revenue raised from ~$15.0B to ~$15.2B− OTEZLA® net sales raised from ~$1.5B to ~$1.6B− Adjusted diluted EPS raised from the range of $8.70-$8.75 to the range of $8.75-$8.80

Q3 2018 Total Net Product Sales

Q3:16 Q3:17 Q3:18

$ M

illio

ns ↑28% ↑11% ↑18%

$0

$500

$1,000

$1,500

$2,000

$2,500

$3,000

$3,500

$4,000

Q3:17 Volume Price FX/Hedge Q3:18

↑18.5%↓0.5%↑14.7% ↑4.3%

Contribution to Q3:18 Total Net Product Sales Growth

$ M

illio

ns

Total Net Product Sales

8

$2,969$3,283

$3,890

Growth Rates = Growth vs. Prior Year Period

Q3 2018 Adjusted Diluted Earnings Per Share

Q3:16 Q3:17 Q3:18

↑28% ↑21%

Dol

lars

Per

Sha

re

↑20%

Q3:17 Oper. Income

OIE Tax Rate

Share Count

Q3:18

Dol

lars

Per

Sha

re

$2.29$0.201$1.91 $0.001 $0.27($0.09)1

9

Contribution to Q3:18 Adjusted Diluted EPSAdjusted Diluted EPS

$1.58

$1.91

$2.29

Growth Rates = Growth vs. Prior Year Period1. Includes net impact of Juno Therapeutics and Impact Biomedicines dilution.

Key P&L Line Items (Adjusted)

Q3:18 ∆ vs.Q3:17

∆ vs.Q2:18

Product Gross Margin 96.2% ↓ 40 bps ↓ 70 bps

R&D Expense% of revenue

$948M24.4% ↑ 320 bps ↓ 50 bps

SG&A Expense% of revenue

$642M16.5% ↑ 60 bps ↓ 110 bps

Operating Margin 55.3% ↓ 420 bps ↑ 80 bps

Effective Tax Rate 16.7% ↑ 20 bps ↓ 10 bps

10

Capital Allocation in Q3 2018Capital Allocation in Q3 2018

Cash flow from operations was approximately $1.9B

Settlement of the Accelerated Share Repurchase (ASR), which commenced in Q2; Repurchased approximately 24 million shares under the ASR

(in $ Billions) 12/31/17 9/30/18

Cash, Cash Equivalents, Marketable Debt Securities and Publicly-Traded Equity Securities

$12.04 $4.38

11

Updated 2018 Guidance

Previous Updated

Total Revenue ~$15.0B ~$15.2B

REVLIMID® Net Sales ~$9.7B Unchanged

POMALYST®/IMNOVID® Net Sales ~$2.0B Unchanged

OTEZLA® Net Sales ~$1.5B ~$1.6B

ABRAXANE® Net Sales ~$1.0B Unchanged

Adjusted Operating Margin ~56.0% ~55.5%

Adjusted Tax Rate ~17% Unchanged

Adjusted Diluted EPS $8.70-$8.75 $8.75-$8.80

Weighted Average Diluted Shares ~735M Unchanged

12

Terrie CurranPresident, I&I


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Q3 2018 I&I Franchise Results

Robust Worldwide Growth for OTEZLA®

– Increasing commercial TRx demand drove Q3:18 net product sales growth of +40% Y/Y– U.S. contracting strategy continues to contribute to topline results– Solid ex-U.S. performance driven by share gains in key markets

14

Enhancing the OTEZLA® Profile– Positive Ph III data for STYLETM in scalp psoriasis– Submitted Behҫet’s disease sNDA in the U.S.– Advancing multiple lifecycle development opportunities

Building a Diversified Portfolio of I&I Assets– Ozanimod RMS regulatory filings in U.S. and EU on track for Q1:19– Positive Ph II 52-week data for HEROESTM trial evaluating RPC4046 in EoE– Advancing development of early- and mid-stage pipeline assets

Net Sales ($M)

$244 $250

$348

$31 $58

$84

Q3:15 Q3:16 Q3:17 Q3:18U.S. ROW

$275$308

$10

$129

$139

Q3 2018 OTEZLA® Net Sales Summary

15

Current Results & Potential Future Growth Drivers

• Q3:18 net sales $432M, +40% Y/Y

– U.S. net sales $348M, +39% Y/Y– International net sales $84M, +45% Y/Y

• Continued growth of OTEZLA® as utilization increases worldwide– Moderate script growth in Q3 due to expected

seasonality– Some inventory build at the channel level– Continued benefit from improved access– Key U.S. performance metrics are on track

• Leadership position in new-to-brand patients• Psoriasis source of business >85% pre-biologic patients

– Strong performance continues in France and Japan

$432

Certain prior year amounts have been rounded +/- $1M to conform to the current year rounding convention

15

16

Multiple Future Growth Drivers for OTEZLA® and Ozanimod

OTEZLA®

• Ph III STYLETM study in scalp psoriasis

• Behҫet’s disease indication

• Ph III ADVANCETM study in mild to moderate plaque psoriasis

• Ph IIIb DISCREETTM study in genital psoriasis

• Ph III SPROUTTM study in pediatric moderate to severe plaque psoriasis

• Ph IV study in moderate psoriatic arthritis

Ozanimod• Ph III YELLOWSTONETM study in Crohn’s disease initiated

• Ph III TRUE NORTHTM enrollment in UC on track for completion in mid-2019

Nadim AhmedPresident, Hematology & Oncology


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Q3 2018 Hematology & Oncology Franchise ResultsQ3 2018 Hematology & Oncology Franchise Results

Strong Net Product Sales and Operating Momentum– Q3:18 net product sales: $3.5B, +16% Y/Y

– Sales performance driven by strong demand across geographies and brands

Growth Drivers Delivering− REVLIMID® continues to grow across geographies with NSCT and post-ASCT maintenance adoption

− POMALYST®/IMNOVID® growth continues through gains in market share and duration

− Positive Phase III AUGMENTTM data with R2 in RR indolent lymphoma expected at ASH

− Positive Phase III data for ABRAXANE®/IO combination regimens in NSCLC and TNBC at ESMO

Advancement and Expansion of Innovative Pipeline− Significant data on pipeline expected at ASH:

− Ph III data on luspatercept (MEDALISTTM and BELIEVETM)

− Data on CAR T: Liso-cel (JCAR017) in CLL, bb21217 in RRMM and JCARH125 in RRMM

− bb2121 clinical program in earlier lines advancing

− Fedratinib U.S. regulatory submission on track for end 2018 18

$150$203

$268$357$107

$138

$149

$156

Q3:15 Q3:16 Q3:17 Q3:18U.S. ROW

$895 $1,154 $1,361$1,667

$558

$738$720

$782

Q3:15 Q3:16 Q3:17 Q3:18U.S. ROW


Q3 2018 IMiD® Net Sales Summary Q3 2018 IMiD® Net Sales Summary

• REVLIMID® Q3:18 net sales $2,449M, +18% Y/Y• POMALYST® Q3:18 net sales $513M, +23% Y/Y• Strong growth with contribution from increased

market share, duration and triplet combinations• Clinical development and potential future growth

drivers:– REVLIMID®

• Positive Ph III data (ECOG E3A06) in smoldering MM• REVLIMID®-based triplet regimens in NDMM Ph III data

readouts expected in NDMM• Ph III ROBUST® study in 1st line ABC-subtype diffuse

large B-cell lymphoma (event driven)

– POMALYST®

• Newer triplet regimens expected to increase share and duration

19

REVLIMID® Net Sales ($M)

Certain prior year amounts have been rounded +/- $1M to conform to the current year rounding convention.

$1,453

$1,892$2,081

$2,449

POMALYST® Net Sales ($M)

$257

$341

$417

$513


Q3 2018 ABRAXANE® Net Sales SummaryQ3 2018 ABRAXANE® Net Sales Summary

$145 $144 $149 $174

$84 $89 $102$114

Q3:15 Q3:16 Q3:17 Q3:18

U.S. ROW

$288

$229$251

$233

Net Sales ($M)

20

• Q3:18 net sales $288M, 15% Y/Y (demand +5% Y/Y)• Potential future growth drivers: Ph III apact® trial of ABRAXANE® in adjuvant pancreatic

cancer data (event driven)

Positive Ph III IO combination trials at ESMO 2018 (TECENTRIQ®+ABRAXANE®):

• IMpassion130* 1st line TNBC

• IMpower131* 1st line squamous NSCLC

• IMpower130* 1st line non-squamous NSCLC

– Ph III IO combination trials published in NEJM:

• IMpassion130* 1st line TNBC (TECENTRIQ®+ABRAXANE®)

• KEYNOTE-407§ 1st line squamous NSCLC

*IMpower130, IMpower131 and IMpassion130 are Genentech, a member of the Roche Group, sponsored clinical trials§ KEYNOTE-407 is a Merck-sponsored trial

Certain prior year amounts have been rounded +/- $1M to conform to the current year rounding convention.

*Luspatercept in collaboration with Acceleron Pharma. bb2121 in collaboration with bluebird bio

Showcasing Our Next-generation Pipeline at ASHShowcasing Our Next-generation Pipeline at ASH

21

• Ph III MEDALISTTM data with luspatercept in MDS*

• Ph III BELIEVETM data with luspatercept in beta-thalassemia*

• Ph I/II data with liso-cel in RR CLL

• Ph I data with bb21217 in RRMM*

• Ph I/II data with JCARH125 in RRMM

• Ph III AUGMENTTM data with R2 in RR indolent lymphoma

Jay Backstrom, MDChief Medical Officer


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Ozanimod RMS NDA & MAA Submissions On Track for Q1:19

23

Data Required for Submission

Non-clinical bridging studies

Utilizing existing PK/PD data

Additional human clinical efficacy and safety studies not needed

Additional Data to Optimize Label

Drug-drug interaction trials in healthy volunteers; Trials are not required for submission

Data have the potential to enhance the opportunity across the broadest patient population

– U.S. approval now expected in RR DLBCL in mid-2020– Data from Ph I CLL trial to be presented at ASH 2018

– MEDALISTTM and BELIEVETM to be presented at ASH– U.S. and EU regulatory submissions expected in H1:19

– U.S. NDA and EU MAA submissions planned for Q1:19– TRUE NORTHTM UC trial enrollment targeted for completion in mid-2019

– U.S. NDA submission in myelofibrosis expected by YE18– EU MAA submission planned in 2019

– Clinical program in earlier lines advancing– U.S. approval expected in highly refractory MM in 2020; KarMMaTM to complete

enrollment by YE18

5 New Late-Stage Products Expected to Launch Through 2020

24

Luspatercept

Liso-cel

Ozanimod

Fedratinib

bb2121

Q3 2018 Conference CallOctober 25, 2018


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Q&A


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Use of Non-GAAP Financial Measures and

Reconciliation Tables


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

Use of Non-GAAP Financial Measures

28


In addition to financial information prepared in accordance with U.S. GAAP, this document also contains certain non-GAAP financial measuresbased on management’s view of performance including:

Adjusted research and development expense Adjusted selling, general and administrative expense Adjusted operating margin Adjusted net income Adjusted earnings per share

Management uses such measures internally for planning and forecasting purposes and to measure the performance of the Company. We believethese adjusted financial measures provide useful and meaningful information to us and investors because they enhance investors’ understanding ofthe continuing operating performance of our business and facilitate the comparison of performance between past and future periods. Theseadjusted financial measures are non-GAAP measures and should be considered in addition to, but not as a substitute for, the information preparedin accordance with U.S. GAAP. When preparing these supplemental non-GAAP financial measures we typically exclude certain GAAP items thatmanagement does not consider to be normal, recurring cash operating expenses but that may not meet the definition of unusual or non-recurringitems. Other companies may define these measures in different ways. The following categories of items are excluded from adjusted financialresults:

Acquisition and Divestiture-Related Costs: We exclude the impact of certain amounts recorded in connection with business combinations anddivestitures from our adjusted financial results that are either non-cash or not normal, recurring operating expenses due to their nature, variabilityof amounts, and lack of predictability as to occurrence and/or timing. These amounts may include non-cash items such as the amortization ofacquired intangible assets, amortization of purchase accounting adjustments to inventories, intangible asset impairment charges and expense orincome related to changes in the estimated fair value measurement of contingent consideration and success payments. We also exclude transactionand certain other cash costs associated with business acquisitions and divestitures that are not normal, recurring operating expenses, includingseverance costs which are not part of a formal restructuring program.


29

Share-Based Compensation Expense: We exclude share-based compensation from our adjusted financial results because share-based compensationexpense, which is non-cash, fluctuates from period to period based on factors that are not within our control, such as our stock price on the datesshare-based grants are issued.

Collaboration-Related Upfront Expenses: We exclude collaboration-related upfront expenses from our adjusted financial results because we do notconsider them to be normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as to occurrenceand/or timing. Upfront payments to collaboration partners are made at the commencement of a relationship anticipated to continue for a multi-yearperiod and provide us with intellectual property rights, option rights and other rights with respect to particular programs. The variability of amountsand lack of predictability of collaboration-related upfront expenses makes the identification of trends in our ongoing research and developmentactivities more difficult. We believe the presentation of adjusted research and development, which does not include collaboration-related upfrontexpenses, provides useful and meaningful information about our ongoing research and development activities by enhancing investors’understanding of our normal, recurring operating research and development expenses and facilitates comparisons between periods and with respectto projected performance. All expenses incurred subsequent to the initiation of the collaboration arrangement, such as research and developmentcost-sharing expenses/reimbursements and milestone payments up to the point of regulatory approval are considered to be normal, recurringoperating expenses and are included in our adjusted financial results.

Research and Development Asset Acquisition Expense: We exclude costs associated with acquiring rights to pre-commercial compounds becausewe do not consider such costs to be normal, recurring operating expenses due to their nature, variability of amounts, and lack of predictability as tooccurrence and/or timing. Research and development asset acquisition expenses includes expenses to acquire rights to pre-commercial compoundsfrom a collaboration partner when there will be no further participation from the collaboration partner or other parties. The variability of amountsand lack of predictability of research and development asset acquisition expenses makes the identification of trends in our ongoing research anddevelopment activities more difficult. We believe the presentation of adjusted research and development, which does not include research anddevelopment asset acquisition expenses, provides useful and meaningful information about our ongoing research and development activities byenhancing investors’ understanding of our normal, recurring operating research and development expenses and facilitates comparisons betweenperiods and with respect to projected performance.


30

Restructuring Costs: We exclude costs associated with restructuring initiatives from our adjusted financial results. These costs include amountsassociated with facilities to be closed, employee separation costs and costs to move operations from one location to another. We do not frequentlyundertake restructuring initiatives and therefore do not consider such costs to be normal, recurring operating expenses.

Certain Other Items: We exclude certain other significant items that may occur occasionally and are not normal, recurring cash operating expensesfrom our adjusted financial results. Such items are evaluated on an individual basis based on both the quantitative and the qualitative aspect of theirnature and generally represent items that, either as a result of their nature or magnitude, we would not anticipate occurring as part of our normalbusiness on a regular basis. While not all-inclusive, examples of certain other significant items excluded from adjusted financial results would be:significant litigation-related loss contingency accruals and expenses to settle other disputed matters and, effective for fiscal year 2018, changes inthe fair value of our equity securities upon the adoption of ASU 2016-01 (Financial Instruments-Overall: Recognition and Measurement ofFinancial Assets and Financial Liabilities).

Estimated Tax Impact From Above Adjustments: We exclude the net income tax impact of the non-tax adjustments described above from ouradjusted financial results. The net income tax impact of the non-tax adjustments includes the impact on both current and deferred income taxes andis based on the taxability of the adjustment under local tax law and the statutory tax rate in the tax jurisdiction where the adjustment was incurred.

Non-Operating Tax Adjustments: We exclude the net income tax impact of certain other significant income tax items, which are not associated withour normal, recurring operations (“Non-Operating Tax Items”), from our adjusted financial results. Non-Operating Tax Items include items whichmay occur occasionally and are not normal, recurring operating expenses (or benefits), including adjustments related to acquisitions, divestitures,collaborations, certain adjustments to the amount of unrecognized tax benefits related to prior year tax positions, the impact of tax reformlegislation commonly referred to as the Tax Cuts and Jobs Act (2017 Tax Act), and other similar items. We also exclude excess tax benefits and taxdeficiencies that arise upon vesting or exercise of share-based payments recognized as income tax benefits or expenses due to their nature,variability of amounts, and lack of predictability as to occurrence and/or timing.

See the attached Reconciliations of GAAP to Adjusted Net Income for explanations of the amounts excluded and included to arrive at the adjustedmeasures for the three- and nine-month periods ended September 30, 2018 and 2017, and for the projected amounts for the twelve-month periodending December 31, 2018.


31


32


33

Appendix


PURSUITS IN SCIENCE


PURSUITS IN SCIENCE

1. Original guidance provided on January 2018 did not include the impact of our acquisition of Juno, which was expected to be dilutive to adjusted diluted EPS by approximately $0.50.2. Updated guidance May 2018 3. Updated guidance July 2018.4. Updated guidance October 2018

2018 Milestones2018 Milestones

Financial Performance Total revenue $14.4B-$14.8B1 Total revenue ~$15.2B4

REVLIMID® net sales ~$9.4B1 REVLIMID® net sales ~$9.7B3

POMALYST® net sales ~$1.9B1 POMALYST® net sales ~$2.0B2

OTEZLA® net sales ~$1.5B1 OTEZLA® net sales ~$1.6B4

ABRAXANE® net sales ~$1.0B1

Adj. operating margin ~60%1 Adj. operating margin ~55.5%4

Adj. diluted EPS $8.70 to $8.901 Adj. diluted EPS $8.75-$8.804

Clinical DataPh III AUGMENTTM – REVLIMID® in R/R FL

Ph III ROBUST ® – REVLIMID® in 1st line ABC-subtype DLBCL- event driven Ph III apact® – ABRAXANE® in adjuvant PanC – event driven

Ph III OPTIMISMM® trial – POMALYST® in 2nd line MM Ph III OTEZLA® in scalp PSOR

Ph III QUAZAR® AML-001 – CC-486 in AML maintenance- event drivenPh III MEDALISTTM – Luspatercept in RS+ MDSPh III BELIEVETM – Luspatercept in beta-thalassemiaPh II OTEZLA ® in UC Trial Enrollment

Complete enrollment in Ph III TRUE NORTHTM – Ozanimod in UC– Ph III TRUE NORTHTM Moved to mid-2019

Complete enrollment in pivotal KarMMaTM trial – bb2121 in RRMM Complete enrollment in TRANSCEND WORLD – Liso-cel in DLBCL

Regulatory Submissions/DecisionsSubmit sNDA for RVd in NDMM Submitted in EU

Submit NDA for Fedratinib in myelofibrosisFDA decision on Ozanimod in RMSFDA decision on OTEZLA ® once-daily formulationSubmit sNDA for OTEZLA® in Behçet’s diseaseSubmit a Marketing Authorization Application (MAA) for Ozanimod in RMS

Trial Initiations Initiate the pivotal program with CC-122 in NHL

Initiate Ph III with OTEZLA® in UC Initiate the pivotal program with Tislelizumab in NSCLC Initiate Ph III with OTEZLA® in mild to moderate PSOR

Initiate Ph III trial with bb2121 in 3rd line+ MMInitiate Ph III trial with Liso-cel in TE 2nd line DLBCL Initiate Ph III COMMANDSTM with Luspatercept in 1st line, lower-risk MDS

Initiate Ph III trial with Ozanimod in SPMS

R&EDFile at least 5 IND’s

35

X

X

X

X

X

REVLIMID®

Del 5q MDS

VIDAZA®

MDS, AML

IDHIFA®

IDH2 RRAML

CC-486 MDS, AML

LuspaterceptMDS, Beta-thalassemia

CC-90009RRAML

FT-1101MDS, AML

MyeloidDisease

10MarketPh I

L E G E N D

REVLIMID®

MCL

ISTODAX®

PTCL, CTCL

REVLIMID®

NHL

CC-122NHL, CLL

Liso-celNHL

CC-486NHL

Lymphoma& Leukemia

10

LuspaterceptMF

CC-90002NHL

Advancing a High Quality Pipeline with Significant Potential

Celgene has an exclusive option to license and/or option to acquire: JTX-2011, Etigilimab, FT-4101, FT-1101, AG-270, and MSC-1

CC-90010NHL

bb21217RRMM

REVLIMID®

NDMM, RRMM

POMALYST®

RRMM

THALOMID®

NDMM, RRMM

CC-220RRMM

bb2121RRMM

CC-92480RRMM

MultipleMyeloma

9

MarizomibGBM

CC-122HCC

CC-90002Solid TumorsCC-90011

Solid Tumors

ABRAXANE®

PanC, NSCLC, mBC

SolidTumors

11EtigilimabSolid Tumors

JTX-2011Solid Tumors

CC-90010Solid Tumors

TislelizumabSolid Tumors

FedratinibMF

FT-1101NHLCC-93269

RRMM

JCARH125RRMM

MSC-1Solid Tumors

Liso-celCLL

GEM333AML

AG-270Solid Tumors

OzanimodUC

Inflammation& Immunology

11

OzanimodMS

OTEZLA®

PSOR, PSA

OTEZLA®

Behçet’s, Scalp PSOR

RPC4046EoE

CC-220SLE

CC-90001 IPF

CC-90006PSOR

FT-4101NASH

OzanimodCD

CC-99677I&I

36

Return On Invested Capital (ROIC): Focused on Efficient Growth

0.0%

5.0%

10.0%

15.0%

20.0%

25.0%

30.0%

35.0%

$0.0

$5.0

$10.0

$15.0

$20.0

$25.0

2009 2010 2011 2012 2013 2014 2015 2016 2017 Q3:18 (TTM)

Capital Base Excluding Cash* Capital Base ROIC Excluding Cash* ROIC

Aver

age

Inve

sted

Cap

ital

$ B

illio

n

ROIC

*For purposes of this calculation, cash includes cash and cash equivalents and marketable debt securities and publicly-traded equity securities.

Footnote: Financial performance is based on GAAP operating income adjusted to reflect amortization of certain charges excluded from 2008 calculation and tax impact. Calculation for 2015 includes expenses driven by the Juno Therapeutics and AstraZeneca collaborations and expenses incurred in connection with the acquisition of Receptos as well as the impact of the August 2015 debt issuance on the capital base. Calculation for 2018 includes expenses incurred in connection with the acquisition of Juno as well as the impact of the February 2018 debt issuance on the capital base. Refer to reconciliation tables for complete calculation methodology. Calculation revised in 2015 for all prior periods to reflect amortization of certain charges excluded from 2008 calculation.

37

Multiple Myeloma Late-Stage/Pivotal Programs

Patient Population RRMM RRMM RRMM

Molecule POMALYST®/IMNOVID® bb2121 bb2121

Trial NameMM-007

OPTIMISMM®

BB2121-MM-001KarMMaTM

BB2121-MM-003KarMMa-3TM

Phase III II III

Target Enrollment 559 140 381

Design

Arm A: POMALYST®/IMNOVID®

(4mg) + bortezomib (1.3 mg/m2 IV) + low-dose dexamethasone to disease

progressionArm B: Bortezomib (1.3 mg/m2 IV) + low-dose dexamethasone to disease

progression

bb2121 autologous CAR T cells (infused at a dose ranging from 15 -45 x 107 CAR T cells after receiving

lymphodepleting chemotherapy)

Arm A: bb2121 autologous CAR T cells (infused at a dose ranging from

15 - 45 x 107 CAR T cells after receiving lymphodepleting

chemotherapy)Arm B: Physicians’ choice

Primary Endpoint Progression Free Survival ORR PFS

Status

Primary endpoint metData presented at ASCO 2018

Submitted in EU; Japan submission planned

Trial enrolling Not yet enrolling

38

MDS/AML/MF Late-Stage/Pivotal Programs

Patient Population Low risk/INT-1 transfusion-dependent MDS

Post induction AML Maintenance

MoleculeCC-486

(Oral azacitidine)CC-486

(Oral azacitidine)

Trial Name AZA-MDS-003 CC-486-AML-001

Phase III III

Target Enrollment 217 472

DesignArm A: CC-486 (300mg daily D1-21 of a

28-D cycle) + best supportive careArm B: Placebo + best supportive care

Arm A: CC-486 (300mg D1-14 of 28-D cycle)

Arm B: Best supportive care

Primary Endpoint RBC-transfusion independence formore than 12 weeks Overall Survival

Status Trial enrollingEnrollment complete

Data expected in 2018 (event driven)

39


Patient Population Anemia in to Very Low-, Low-, or Intermediate-Risk MDS

Red Blood Cell Transfusion Dependent Beta-Thalassemia

Molecule Luspatercept Luspatercept

Trial Name MEDALISTTM BELIEVETM

Phase III III


DesignArm A: Luspatercept (starting dose of 1.0 mg/kg

subcutaneous injection every 3 weeks)Arm B: Placebo (subcutaneous injection every 3

weeks)

Arm A: Luspatercept (1 mg/kg) + best supportive care

Arm B: Placebo + best supportive care

Primary Endpoint Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 weeks

Proportion of subjects with hematological improvement from Week 13 to Week 24 compared to

12-week prior to randomization

StatusPrimary endpoint met

Data expected at ASH 2018Regulatory submissions planned in H1:19

Primary endpoint metData expected at ASH 2018

Regulatory submissions planned in H1:19

40


Patient Population ESA Naïve Very Low, Low or Intermediate Risk MDS IDH2 Mutant RR AML

Molecule Luspatercept IDHIFA®

Trial Name COMMANDSTM IDHENTIFYTM

Phase III III


DesignArm A: Luspatercept (1.0 mg/kg SC every 3 weeks)

Arm B: Epoetin alfa (450 IU/kg SC weekly)

Arm A: IDHIFA® (100 mg daily, 28-D cycle) + best supportive care

Arm B: Best supportive care

Primary Endpoint Red blood cell transfusion independence at 24 weeks Overall Survival

Status Not yet recruiting Trial enrolling

41

Lymphoma Late-Stage/Pivotal Programs

Patient Population Relapsed or Refractory Follicular Lymphoma

Newly Diagnosed Follicular Lymphoma

Untreated Activated B-Cell DLBCL

Molecule REVLIMID® REVLIMID® REVLIMID®

Trial NameAUGMENTTM

NHL-007RELEVANCE®

ROBUST®

DLC-002

Phase III III III

Target Enrollment 358 1,031 570

Design

Arm A: REVLIMID® (10-20mg, D1-21) + rituximab (375 mg/m2 weekly for cycle 1 then D1 of cycles 2-5 for 5 28-D cycles)

Arm B: Placebo (D1-21) + rituximab (375 mg/m2 weekly for cycle 1 then D1

of cycles 2-5 for 5 28-D cycles)

Arm A: REVLIMID® (starting dose 20mg, D2-22 for up to 18 D cycles) + rituximab (starting dose 375 mg/m2

weekly for up to 12 28-D cycles)Arm B: Physician’s choice of

Rituximab-CHOP, Rituximab-CVP or Rituximab-bendamustine

Arm A: REVLIMID® (15mg, D1-14) + R-CHOP21 (6 21-D cycles)

Arm B: Placebo + R-CHOP21 (6 21-D cycles)

Primary Endpoint Progression Free Survival Complete Response Rate and Progression Free Survival Progression Free Survival

Status

Primary endpoint metData to be presented at ASH 2018Regulatory submissions planned in

Q1:19

Trial did not achieve superiority in co-primary endpoints

Data presented at ASCO 2018

Data expected in 2018 (event driven trial

42


Patient Population Relapsed or Refractory Indolent Lymphoma Relapsed or Refractory B-cell NHL

Molecule REVLIMID®Liso-cel

(lisocabtagene maraleucel; JCAR017)

Trial NameMAGNIFYTM

NHL-008TRANSCEND-NHL-001

Phase III I


Design

Arm A: REVLIMID® (10-20mg, D1-21) + rituximab (375 mg/m2

weekly for cycle 1 then D1 of cycles 3, 5,7,9 and 11 for 12 28-D cycles) followed by REVLIMID® (10mg, D1-21) + rituximab (375 mg/m2 D1 of cycles 13,15,17,19,21,23,25,27 and 29 for 18 28-D

cycles) followed by REVLIMID® (10mg, D1-21 until disease progression, 28 D cycle)

Arm B: REVLIMID® (10-20mg, D1-21) + rituximab (375 mg/m2

weekly for cycle 1 then D1 of cycles 3, 5,7,9 and 11 for 12 28-D cycles) followed by REVLIMID® (10mg, D1-21) + rituximab (375 mg/m2 D1 of cycles 13,15,17,19,21,23,25,27 and 29 for 18 28-D

cycles)

Arm A: JCAR017 single-dose scheduleArm B: JCAR017 2-dose schedule

Primary Endpoint Progression Free Survival Objective Response Rate; Safety

StatusTrial enrolling

Data expected in 2020Enrollment complete

43


Patient Population

Aggressive Relapsed orRefractory B-Cell Lymphoma

MoleculeLiso-cel

(lisocabtagene maraleucel; JCAR017)

Trial Name TRANSCEND WORLD

Phase II

Target Enrollment 124

DesignArm A: JCAR017 (1 x 108 positive

transfected viable T cells on D 1; 2 to 7 days after completion of lymphodepleting

chemotherapy).

Primary Endpoint Overall Response Rate

Status Trial enrolling

44

Solid Tumor Late-Stage/Pivotal Programs

Patient Population Adjuvant Therapy in Surgically Resected Pancreatic Cancer Newly Diagnosed Glioblastoma

Molecule ABRAXANE® Marizomib

Trial NamePANC-003

apact®EORTC-BTG-1709

Phase III III


Design

Arm A: ABRAXANE® (125 mg/m2); Gemcitabine (1000 mg/m2) D1,8,15 for 6 28-

D cyclesArm B: Gemcitabine (1000 mg/m2) D1,8,15

for 6 28-D cycles

Arm A: Radiotherapy + temozolomide + marizomib followed by adjuvant

temozolomide + marizomib

Arm B: Radiotherapy + temozolomide followed by adjuvant temozolomide

Primary Endpoint Disease Free Survival Overall Survival

StatusEnrollment complete

Data expected in 2018 (event driven)Trial enrolling

45

I&I Late-Stage/Pivotal Programs

Patient Population Active Behçet’s Disease Scalp Psoriasis

Molecule OTEZLA® OTEZLA®

Trial NameBCT-002RELIEF®

SPSO-001STYLETM

Phase III III


DesignArm A: Placebo (for 12 weeks) followed by OTEZLA® (30mg twice daily for 52 weeks)Arm B: OTEZLA® (30mg twice daily for 64

weeks)

Arm A: Placebo (for 16 weeks) followed by OTEZLA® (30mg twice daily for 16 weeks)

Arm B: Placebo (for 32 weeks)

Primary Endpoint Area under the curve (AUC) for the number of oral ulcers from baseline through week 12

Proportion of subjects with ScPGA score of clear (0) or almost clear (1) with at least a 2-

point reduction from baseline at Week 16

Status

Met primary endpointData presented at AAD 2018

sNDA submitted; Additional regulatory submissions planned

Met primary endpoint

46

I&I Late Stage Programs

Patient Population Moderate to Severe Ulcerative Colitis

Moderately to Severely Active Crohn's Disease

Moderately to Severely Active Crohn's Disease

Molecule Ozanimod Ozanimod Ozanimod

Trial Name TRUE NORTHTM RPC01-3201 RPC01-3202

Phase III III III

Target Enrollment 900 600 600

DesignArm A: Ozanimod (1mg daily) for

induction and maintenanceArm B: Placebo induction and

maintenance

Arm A: Ozanimod (0.92 mg daily) with a 7-D dose escalation

Arm B: Placebo

Arm A: Ozanimod (0.92 mg daily) with a 7-D dose escalation

Arm B: Placebo

Primary EndpointClinical remission assessed by Mayo component sub-scores at week 10

Clinical remission assessed by Mayo component sub-scores at week 52

Proportion of subjects with a CDAI score < 150 at Week 12

Proportion of subjects with a CDAI score < 150 at Week 12

Status Enrollment expected to complete by mid-2019 Trial enrolling Trial enrolling

47

I&I Late Stage Programs

Patient Population

Maintenance for Moderately to Severely Active Crohn's Disease

Relapsing Multiple Sclerosis Relapsing Multiple Sclerosis

Molecule Ozanimod Ozanimod Ozanimod

Trial Name RPC01-3203 SUNBEAMTM RADIANCETM

Phase III III III

Target Enrollment 485 ~1,300 ~1,300

DesignArm A: Ozanimod (0.92 mg daily

for 40 weeks)Arm B: Placebo (daily for 40

weeks)

Arm A: Ozanimod (0.5mg daily) + placebo IM weekly

Arm B: Ozanimod (1mg daily) + placebo IM weekly

Arm C: Placebo (daily) + beta-interferon IM weekly

Arm A: Ozanimod (0.5mg daily) + placebo IM weekly

Arm B: Ozanimod (1mg daily) + placebo IM weekly

Arm C: Placebo (daily) + beta-interferon IM weekly

Primary Endpoint

Proportion of subjects with a CDAI score of < 150 at week 40

Proportion of subjects with a (SES-CD) score decrease from baseline of ≥ 50% at week 40

Annualized relapse rate at month 12 Annualized relapse rate at month 24

Status Trial not yet enrolling

Data presented at ECTRIMS 2017 and AAN 2018

NDA expected to be resubmitted in Q1:19; MAA expected to be submitted in

Q1:19

Data presented at ECTRIMS 2017 and AAN 2018

NDA expected to be resubmitted in Q1:19; MAA expected to be submitted in Q1:19

48

q3 2018 conference call - s24.q4cdn.com · 10/25/2018 · q3 2018 conference call mark alles,...

Documents